52 North

52 North is a medical technology startup. The company's device is portable, easy to use, and provides a way to measure patients' neutrophil count and CRP at home, helping to identify patients at risk of neutropenic sepsis, a fatal side effect of chemotherapy. This enables patients to access a reliable and cost-effective device that allows for rapid management of cancer-related conditions. The company’s product, Neutrocheck®, is a low-cost point-of-care testing (POCT) device for use outside the hospital, comprising a small portable device and a digital platform. Through a finger-prick blood sample, patients can quickly assess their risk of developing NS at home, which also helps doctors accurately triage patients.